Novartis's Cosentyx Climbs Despite Competitors And COVID-19
First Billion Dollar Quarter For Anti-IL-17 Blockbuster
CEO Vas Narasimhan told Scrip how impressed he was by the resilience of the brand and while Cosentyx is holding its market share in dermatology, its rheumatology sales are continuing to fly high.
You may also be interested in...
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
The Australian company's off-the-shelf cell therapy fell foul of the US FDA for graft-versus-host disease recently but Novartis is backing remestemcel-L as a potential treatment for acute respiratory distress syndrome.
Having been under GSK's umbrella since 1985, SR One is striking out on its own, having closed the largest first-time VC fund this year.